Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLYB116 in healthy participants
NCT06797375Phase 1Completed
- Sponsor
- Rallybio
- Start
- Apr 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RLYB116 in Hematologic disease and autoimmune disease (2 arms), sponsored by Rallybio. Primary endpoint: Number of participants with treatment related adverse events at Day 99. Started Apr 2025; status: completed.
02
Drugs
RLYB116
03
Conditions
Hematologic diseaseautoimmune disease
Beyond the preview
Go deeper on NCT06797375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797375.